Rituximab-associated infections.

  title={Rituximab-associated infections.},
  author={Juan C. Gea-Banacloche},
  journal={Seminars in hematology},
  volume={47 2},
After more than 10 years of use, rituximab has proven to be remarkably safe. However, accumulated evidence now suggests that under some circumstances it may significantly increase the risk of infections. This risk is difficult to quantify because of confounding factors (namely, concomitant use of immunosuppressive or chemotherapeutic agents and underlying conditions), as well as under-reporting. Increased number of infections has been documented in patients treated with maintenance rituximab… 

Tables from this paper

Management of patients with overt or resolved hepatitis B virus infection undergoing rituximab therapy

The safety of RTX in patients with overt or resolved HBV infection, providing recommendations for its safe use in such patients is reviewed.

Rituximab-Associated Occurrence of Disseminated Miliary Tuberculosis

There is accumulating evidence supporting the concept that B-cell immunity does indeed play a role in defense against MTB, and B cells have been identified as having an influence on bacillary containment.

Infections in vasculitis.

  • L. Guillevin
  • Medicine, Biology
    Best practice & research. Clinical rheumatology
  • 2013

Rituximab in people living with HIV affected by immune-mediated renal diseases: a case-series

The outcome of four PLWH who underwent RTX therapy after the diagnosis of immune-mediated renal disease was described, and the main RTX-associated adverse effects were leukopenia, late-onset neutropenia and decline of CD4+ and CD8+ T-cell counts.

Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis

R-C is superior to standard C in terms of overall response and it does not increase the overall incidence of severe infection, and more studies are needed to explore the potential effect of R on silent and chronic viral infections.

Prolonged Immunodeficiency in a Patient with Burkitt's Lymphoma after Treatment with Rituximab and Chemotherapy

The need for an immunological work-up in lymphoma patients before initiation of treatment is illustrated because of the increased incidence of lymphoma in patients with immunodeficiencies.


Multivariate analysis for mortality showed that age >60 years, failure to achieve a complete response, and development of an infectious complication increased the risk of death, and it is important to perform a screening test for TB in patients who will receive rituximab and maintain a constant monitoring to detect an infectious process and begin treatment as soon as possible.

A case of severe acute hepatitis C and delayed antibody production due to rituximab therapy

The long window (8 months) between HCV infection and the development of anti-HCV antibodies observed in the present case may have been due to a B cell disorder caused by rituximab therapy.

Development of Enteroviral Aseptic Meningitis After Rituximab Treatment of Non-Hodgkin Lymphoma

A case of aseptic meningitis is reported in a patient with non-Hodgkin lymphoma after treatment with rituximab in combination with cytotoxic chemotherapy and successful treatment with intravenous immunoglobulin therapy.

Severe hepatitis associated with varicella zoster virus infection in a patient with diffuse large B cell lymphoma treated with rituximab-CHOP chemotherapy

It is suggested that the use of chemotherapy for immune-suppressed elderly lymphoma patients may involve the risk of severe VZV infection, particularly in patients who are not recipients of hematopoietic stem cell transplantation.



Fulminant hepatitis B virus reactivation with concomitant listeriosis after fludarabine and rituximab therapy: case report

A case of a woman with acute prolymphocytic leukemia who received chemotherapy containing fludarabine and cyclophosphamide, followed by the CD 20 monoclonal antibody, rituximab developed fatal reactivation of hepatitis B with fulminant liver failure 3 months after completing treatment.

Cytomegalovirus infection following renal transplantation in patients administered low‐dose rituximab induction therapy

  • H. NishidaH. Ishida K. Tanabe
  • Medicine, Biology
    Transplant international : official journal of the European Society for Organ Transplantation
  • 2009
Low‐dose rituximab induction therapy in renal transplant recipients appears to have no influence on the incidence of CMV infection and CMV seroconversion, but anti‐CMV prophylaxis therapy has to consider, because of high incidents ofCMV infection, especially forCMV seronegative recipients who received ritUXimab.

Increased incidence of interstitial pneumonia by CHOP combined with rituximab

The results suggest that R-CHOP raises the incidence of IP, possibly through increasing the susceptibility to P. jirovecii and fungal infection, and the need for prophylactic antifungals and ST should be evaluated by randomized controlled trials.

High incidence of non-neutropenic infections induced by rituximab plus fludarabine and associated with hypogammaglobulinemia: a frequently unrecognized and easily treatable complication.

Indolent histology, female sex and fludarabine + rituximab -chemotherapy significantly correlated with frequency of NNI but multivariate analysis picked fludARabine - ritUXimab followed by female gender as the only two independent variables predictive of N NI.

Rituximab for refractory childhood autoimmune hemolytic anemia.

Treatment with rituximab appears promising for refractory AIHA; if may obviate the need for prednisone and may result in sustained disease remissions in some patients.

Three cases of Pneumocystis jirovecii pneumonia (PCP) during first‐line treatment with rituximab in combination with CHOP‐14 for aggressive B‐cell non‐Hodgkin’s lymphoma

This preliminary report did not mention PCP as verified cause of pneumonia, but adding cotrimoxazole was successful in 56 subsequent lymphoma patients, and no increased toxicity was found after adding rituximab to a 21-d interval chemotherapy scheme, suggesting a relation with the dose interval rather than the use of ritUXimab.

Infectious complications of rituximab in patients with lymphoma during maintenance therapy: a systematic review and meta-analysis

Patients who received rituximab maintenance treatment have higher risk of neutropenia and infection than those who did not, and previously treated patients particularly with fludarabine containing regimens are more susceptible to infectious complications and require extended vigilance.

Monoclonal antibody treatment of mixed cryoglobulinemia resistant to interferon alpha with an anti-CD20.

The results indicate that rituximab has clinical and biologic activity in patients with HCV(+) MC, however, in view of the increased viremia in the responders, additional modes of application and combination of ritUXimab with other agents need to be investigated.

Late onset Pneumocystis pneumonia in patients receiving rituximab for humoral renal transplant rejection

Two cases of Pneumocystis pneumonia occurring nearly 3’years after administration of rituximab for refractory AbMR are reported herein, highlighting the need for ongoing vigilant observation in patients who have received ritUXimab and the importance of clinical trials to establish the role of r ituximabs in prevention and treatment of AbMR.